Stock · Euronext Dublin
Should you buy Glanbia stock?
A global nutrition group behind brands like Optimum Nutrition, with steady growth and rising margins but a sharp share-price fall and a fuller multiple. Here is our rating and how to buy it.
Key points
- Euronext Dublin: GL9. Irish nutrition group, also listed in London (GLB).
- 2024 revenue $3.84bn (+5.8%), EBITDA $551.3m (+11.7%), margin 14.4%.
- Down about 32.2% year-to-date, but P/E ≈ 22x is still not cheap.
- Global brands (Optimum Nutrition) across 30+ countries; execution and consumer demand are the swing factors.
01Our review
Glanbia at a glance
Glanbia is a global nutrition and packaged-food group with operations in more than 30 countries and leading brands such as Optimum Nutrition, organised around Performance Nutrition, Health & Nutrition and Dairy Nutrition. The 2024 results showed revenue of about $3.84bn (+5.8% year on year), EBITDA of roughly $551.3m (+11.7%) with the margin rising to 14.4% (from 13.6%), adjusted EPS growth of about 6.8% in constant currency, cash-flow conversion of 88%, and a 2024 total dividend of €0.3897 per share (+10%, a 30.1% payout). Management has been reshaping the portfolio, including the $355m acquisition of Flavor Producers LLC and a cost-saving programme targeting $50m+ a year by 2027. The catch is the share price: down about 32.2% year-to-date, yet still on a P/E around 22x, so the market is pricing recovery, not distress.
Strengths
- Global nutrition brands: Optimum Nutrition and a footprint across 30+ countries.
- Improving profitability: 2024 EBITDA +11.7%, margin up to 14.4%.
- Strong cash generation: 88% cash-flow conversion and a growing dividend (+10%).
- Active portfolio management: Flavor Producers acquisition and a $50m+ cost programme.
Watch-outs
- Weak momentum: down about 32.2% year-to-date.
- Not cheap on the fall: a P/E around 22x still prices a recovery in demand and execution.
02Snapshot
Glanbia in brief
Fundamentals verified as of 22 July 2026.
04Our verdict
Our verdict, backed by sources
Quality brands, recovery already priced
A global nutrition group with strong brands, improving margins and good cash generation, but the shares have fallen hard while the multiple (P/E ≈ 22x) still assumes a recovery. A reasonable holding for patient investors who back the brands and portfolio reshaping, sized modestly.
This is analysis, not advice. The bull case: Glanbia owns leading nutrition brands (Optimum Nutrition) across 30+ countries, grew 2024 revenue about 5.8% to $3.84bn, lifted EBITDA 11.7% with margin up to 14.4%, converts 88% of profit to cash, and is reshaping the portfolio (Flavor Producers, a $50m+ cost programme).
The bear case: the shares are down about 32.2% year-to-date, consumer-nutrition demand can be volatile, and even after the fall the P/E of roughly 22x still prices a recovery. Execution on the turnaround has to deliver.
Our take: a good business with real brands, but the multiple already assumes a rebound, so entry price and patience matter. Suitable for long-term investors, sized modestly. As always, no invented price target.
05Get started
How to buy Glanbia stock
Two routes, both from regulated brokers. A broker comparison is further down.
Cash / spot
Buy the real share (cash)
You own the share and collect the dividend. Cost is a small commission per order; the Dublin (GL9) line trades in EUR, so there is no FX fee for an Irish investor. Irish residents typically pay capital gains tax on gains and income tax on dividends: check your own situation with a broker or adviser. Best for buy-and-hold investors.
CFD (leveraged)
Trade via CFD (leverage)
A CFD tracks the price with leverage that amplifies gains and losses; costs are the spread plus overnight financing. Short-term, risk-aware traders only; most retail CFD accounts lose money.
For long-term investors, buying the real share in an ordinary brokerage account is simplest. Compare brokers on Irish/Euronext commissions below.
06Playbook
6 practical tips for buying Glanbia
-
Judge the turnaround
The case rests on portfolio reshaping and margin gains delivering as planned.
-
Respect the drawdown
Down about 32.2% year-to-date; a falling price is not automatically a bargain.
-
Mind the multiple
A P/E around 22x still prices a recovery, so entry price matters.
-
Use the Dublin line
The GL9 line trades in EUR, avoiding FX costs for an Irish investor.
-
Mind Irish tax
Check how capital gains and dividends are taxed in your situation.
-
Size modestly
Consumer-demand and turnaround risk justify a smaller position in a diversified portfolio.
08Where to invest
Where to buy Glanbia stock
For Glanbia, prioritise low commissions on Irish and Euronext listings. Compare regulated brokers side by side.
Compare brokers for stocksGlanbia stock FAQ
- Yes. The 2024 total dividend was about €0.3897 per share (+10% year on year), a yield of roughly 2.9% with a payout ratio around 30.1%. The case combines modest income with growth.
- Glanbia is a global nutrition group with a large US business, so it reports in US dollars ($3.84bn in 2024) even though the Dublin (GL9) share line trades in euros.
- Not obviously. Despite being down about 32.2% year-to-date, the P/E of roughly 22x still prices in a recovery in demand and execution, so it is not a clearly cheap valuation.
- We don't publish one. We refuse to invent a figure or a fake consensus. When a credible, sourced analyst consensus exists we may cite it with its date; otherwise we say we don't have one.
Why trust HelloBrokers on this
Independent editorial team. We are not paid by Glanbia, and we don't publish invented price targets or a fake bank consensus. Ratings follow our methodology; broker referrals (disclosed on each page) fund our work and never change our verdict.
This content is for information only and is not investment advice, a recommendation or a solicitation. Past performance does not predict future returns. Investing carries a risk of capital loss; CFDs amplify that risk. Do your own research and consider professional advice before investing.